TG THERAPEUTICS, INC.— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$193M
↑+78.0% +$84Mvs FY2024 (Q4)
Gross Profit
$154M
↑+66.4% +$62Mvs FY2024 (Q4)
Operating Income
$50M
↑+71.2% +$21Mvs FY2024 (Q4)
Net Income
$23M
↑+18.1% +$4Mvs FY2024 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $193M | $108M |
| COGS | $38M | $15M |
| Gross Profit | $154M | $93M |
| R&D | $41M | $24M |
| SG&A | $63M | $39M |
| D&A | $0 | $9K |
| Other OpEx | $0 | $445K |
| Operating Income | $50M | $29M |
| Interest Exp. | $5M | $8M |
| Other Non-Op | $0 | $0 |
| Pretax Income | $45M | $21M |
| Tax | $22M | $2M |
| Net Income | $23M | $20M |
QuarterCharts · SEC EDGAR data · TGTX · Comparing FY2025 (Q4) vs FY2024 (Q4)